Search
for
Sort by
Research 901–930 of 1000+
- Familial Sexual Precocity
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- Mammary Cells with Active Wnt Signaling Resist ErbB2-Induced Tumorigenesis
- Docetaxel and permanent alopecia
- Women's Skin throughout Lifetime
- Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area
- The financial burden of scalp cooling therapy: A nonprofit organization data analysis
- Ovarian intratumoral 21-hydroxylase deficiency in a postmenopausal hirsute woman
- Role of sgk1 in cancer: a bibliometric analysis from 2013 to 2023—review article
- Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice
- GRANULOSA‐THECA CELL TUMOR IN A ONE‐YEAR‐OLD INFANT
- Biological Potential and Therapeutic Effectiveness of Hinokiflavone in Medicine: The Effective Components of Herbal Medicines for Treatment of Cancers and Associated Complications
- The Psychological Impact of Aesthetic Surgery: A Mini-Review
- Chemotherapy-induced alopecia: A novel observation
- Hirsutism in a Female Adolescent Induced by Long-Acting Injectable Risperidone
- Tissue Engineering in Cosmetics and Dermatology: A New Era of Innovation and Application
- Cemotherapi Induce Alopecia Due Carboplatin-Paclitaxel Regiment
- Oral minoxidil for the treatment of late alopecia in cancer survivors.
- Whole brain radiotherapy with partial hair-sparing technique-a feasibility study
- Mycosis Fungoides in Elderly Adults—A Diagnostic Challenge
- Visual Diagnosis: An Adolescent Female Who Has Increasing Hair Growth
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor‐Hair Serum for the Prevention of Chemotherapy‐Induced Alopecia
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Robotic Horizons in Plastic Surgery: A Look Toward the Future
- KRT17: A Key Driver of Cancer Therapy Resistance and Emerging Therapeutic Target
- Mirtazapine-induced Gynecomastia: An Unknown Side Effect?
- A Prospective Observational Study for Assessment of Chemotherapy-Induced Adverse Drug Reactions in Cancer Patients